{"id":"W4205969691","doi":"10.3324/haematol.2021.279012","title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Cilag; Juno Therapeutics; Kite Pharma; Cancer Research UK; Genentech; Horizon Therapeutics; Pfizer; Moderna; Incyte; Pharmacyclics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; AstraZeneca; Barts Charity; Exelixis; Karyopharm Therapeutics; Unum Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Gilead Sciences; MorphoSys; Celgene; TG Therapeutics; Amgen; GlaxoSmithKline","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001477069,0.0008783814,0.005260473,0.0008024637,0.0006956901,0.00004038031,0.001053033,0.0003286028,0.002888191],"category_scores_gemma":[0.0007893121,0.0005305194,0.002080514,0.003497701,0.002178782,0.0001136046,0.0006725813,0.0004292452,0.00002545471],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.3317148,"about_ca_system_score_gemma":0.1157102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002535283,"about_ca_topic_score_gemma":0.001063965,"domain_scores_codex":[0.9919623,0.000902639,0.002149523,0.001267627,0.002451783,0.001266182],"domain_scores_gemma":[0.9929442,0.002368267,0.00152221,0.002360838,0.0004223564,0.0003820999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8176984,0.0004514612,0.000002029641,0.0003904195,0.007246044,0.001324621,0.001797733,0.167874,0.0003290661,0.001585047,0.0005938042,0.0007074323],"study_design_scores_gemma":[0.5896574,0.008300942,0.000004270477,0.0001057862,0.006997587,0.0005648253,0.0002163651,0.3880878,0.001565447,0.00003018532,0.004134812,0.000334586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855472,0.00443143,0.0002518965,0.0001836294,0.0005522518,0.006088244,0.0002380752,0.0001560368,0.002551278],"genre_scores_gemma":[0.992657,0.001156229,0.0001838173,0.00006653169,0.0001780881,0.001735364,0.000294525,0.00008321652,0.003645216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2280409,"threshold_uncertainty_score":0.9997146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04504888166279691,"score_gpt":0.308024079257522,"score_spread":0.2629751975947251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}